Fludarabine and rituximab for relapsed or refractory hairy cell leukemia

Blood

Volumn 119, Issue 9, 2012, Pages 1988-1991

  Gerrie, Alina S ^a   Zypchen, Leslie N ^a   Connors, Joseph M ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; FLUDARABINE; PENTOSTATIN; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84857756101     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-371989     Document Type: Article

References (22)

1. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood. 1994; 84(12):4061-4063.
2. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13(4):974-982.
3. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117-1121. (Pubitemid 20149529)
4. Tallman MS, Hakimian D, Variakojis D, et al.Asingle cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80(9):2203-2209.
5. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients: a French retrospective study of 238 patients. Leukemia. 2003;17(1):45-51. (Pubitemid 36175887)
6. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104(11):2442-2448. (Pubitemid 41691566)
7. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740.
8. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol. 2008;143(2):296-298.
9. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107(12):4658-4662. (Pubitemid 43882611)
10. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer. 2007;110(10):2240-2247. (Pubitemid 350100746)
11. Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer. 1991;67(5):1291-1293.
12. Kraut EH, Chun HG. Fludarabine phosphate in refractory hairy cell leukemia. Am J Hematol. 1991;37(1):59-60.
13. Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(10):1590-1596. (Pubitemid 46646221)
14. Klasa RJ, Meyer RM, Shustik C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol. 2002;20(24):4649-4654. (Pubitemid 36025281)
15. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23(4):694-704. (Pubitemid 46224168)
16. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as frontline treatment for patients with follicular lymphoma. J Clin Oncol. 2004;22(13):2654-2661. (Pubitemid 41103753)
17. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349-1355.
18. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6-14. (Pubitemid 36025880)
19. Gerrie A, Toze C, Ramadan K, et al. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. Leuk Lymphoma. 2012; 53(1):77-82.
20. Foucar K, Falini B, Catovsky D, Stein H. Hairy cell leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., eds. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008;188-190.
21. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in downregulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7(3):709-723. (Pubitemid 32707998)
22. Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma. 2009;50(suppl 1):32-37.